We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
+13.18%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$25B
AUM Growth
+$2.35B
Cap. Flow
+$638M
Cap. Flow %
2.55%
Top 10 Hldgs %
85.68%
Holding
126
New
11
Increased
17
Reduced
63
Closed
6

Top Buys

Rank Stock Value
1
ONC
BeOne Medicines Ltd
ONC
+$358M
2
PRLD icon
Prelude Therapeutics
PRLD
+$286M
3
KYMR icon
Kymera Therapeutics
KYMR
+$59.8M
4
GBT
Global Blood Therapeutics, Inc.
GBT
+$55.5M
5
NRIX icon
Nurix Therapeutics
NRIX
+$45.1M

Top Sells

Rank Stock Value
1
PRNB
Principia Biopharma Inc. Common Stock
PRNB
+$94.5M
2
NBIX icon
Neurocrine Biosciences
NBIX
+$26.6M
3
TCDA
Tricida, Inc. Common Stock
TCDA
+$21.6M
4
INSM icon
Insmed
INSM
+$21.6M
5
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$16.5M

Sector Composition

Rank Sector Weight
1 Healthcare 99.7%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AUTL
76
Autolus Therapeutics
AUTL
$641M
$5.37M 0.02%
461,324
-24,300
-5% -$352K
RETA
77
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$5.18M 0.02%
53,183
-2,800
-5% -$350K
REPL icon
78
Replimune Group
REPL
$1.39B
$4.76M 0.02%
206,586
+201,445
+3,918% +$4.59M
CRNX icon
79
Crinetics Pharmaceuticals
CRNX
$8.99B
$4.74M 0.02%
302,320
-15,537
-5% -$238K
IFRX icon
80
InflaRx
IFRX
$309M
$4.29M 0.02%
1,007,559
-50,996
-5% -$235K
ITOS
81
DELISTED
iTeos Therapeutics
ITOS
$4.13M 0.02%
+167,562
New +$4.51M
AKRO
82
DELISTED
Akero Therapeutics
AKRO
$4.06M 0.02%
+131,788
New +$4.61M
LEGN icon
83
Legend Biotech
LEGN
$4.24B
$3.96M 0.02%
128,200
-6,800
-5% -$229K
DNLI icon
84
Denali Therapeutics
DNLI
$3.98B
$3.56M 0.01%
99,400
-5,500
-5% -$166K
PASG icon
85
Passage Bio
PASG
$14.3M
$3.42M 0.01%
13,053
-697
-5% -$240K
OVID icon
86
Ovid Therapeutics
OVID
$547M
$3.39M 0.01%
590,761
+132,508
+29% +$887K
TARA icon
87
Protara Therapeutics
TARA
$228M
$3.36M 0.01%
199,671
– –
CHMA
88
DELISTED
Chiasma, Inc. Common Stock
CHMA
$3.19M 0.01%
742,133
-204,568
-22% -$979K
INZY
89
DELISTED
Inozyme Pharma
INZY
$3.12M 0.01%
+118,500
New +$2.94M
XLRN
90
DELISTED
Acceleron Pharma
XLRN
$2.88M 0.01%
25,640
-1,360
-5% -$135K
ALEC icon
91
Alector
ALEC
$264M
$2.8M 0.01%
265,600
-14,400
-5% -$233K
KZR
92
DELISTED
Kezar Life Sciences
KZR
$2.78M 0.01%
57,496
-2,504
-4% -$120K
CNST
93
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$2.7M 0.01%
133,333
– –
GMDA
94
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
$2.63M 0.01%
633,324
-33,342
-5% -$142K
TCRR
95
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
$2.49M 0.01%
+122,532
New +$2.15M
NTLA icon
96
Intellia Therapeutics
NTLA
$1.8B
$2.43M 0.01%
122,238
-6,300
-5% -$131K
VKTX icon
97
Viking Therapeutics
VKTX
$3.95B
$2.35M 0.01%
404,200
-20,800
-5% -$143K
DRNA
98
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$2.04M 0.01%
113,135
-6,200
-5% -$128K
RCUS icon
99
Arcus Biosciences
RCUS
$3.86B
$1.98M 0.01%
115,425
-6,109
-5% -$136K
NGM
100
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$1.88M 0.01%
118,100
-6,300
-5% -$115K
1 2 3
4
5

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q3 2020 Portfolio in Review

As of Q3 2020, Julian Baker held 126 positions worth $25B, up 10% from $22.7B the previous quarter. Its ten largest holdings account for 86% of the portfolio.

Julian Baker's Q3 2020 filing shows 11 new, 17 increased, 63 reduced and 6 closed positions. Its largest new stake was Prelude Therapeutics: 10,118,636 shares worth $305M. The largest sale was Principia Biopharma Inc. Common Stock, an estimated $94.5M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Financials.

  • Julian Baker's largest Q3 2020 buy was Prelude Therapeutics: 10,118,636 shares worth $305M.
  • Julian Baker added most to BeOne Medicines Ltd in Q3 2020, an estimated $358M increase.
  • Julian Baker's biggest Q3 2020 reduction was Neurocrine Biosciences, cutting an estimated $26.6M.
  • Julian Baker fully exited Principia Biopharma Inc. Common Stock in Q3 2020, selling an estimated $94.5M.
  • Julian Baker's ten largest holdings make up 86% of its $25B portfolio in Q3 2020.
  • Julian Baker opened 11 new positions and closed 6 in Q3 2020.
  • Julian Baker's portfolio value rose 10% quarter-over-quarter to $25B.

Based on Baker Bros. Advisors's 13F filing for Q3 2020, filed 16 Nov 2020.